Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 17.
doi: 10.1097/MAT.0000000000002560. Online ahead of print.

Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support

Affiliations

Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support

Nadia Chaudhry-Waterman et al. ASAIO J. .

Abstract

Bivalirudin is a direct thrombin inhibitor that inhibits both circulating thrombin and fibrin-bound thrombin, giving it the ability to not only prevent thrombus extension, but also more directly facilitate clot resolution than heparin. Although still not yet the standard of care, bivalirudin has become more frequently used for anticoagulation in patients on mechanical circulatory support. In patients who develop large or critically localized thrombosis, requiring catheter-directed therapy, alteplase remains the drug of choice. Here we describe three cases of children, all of whom were on mechanical circulatory support, who required catheter-directed thrombolysis. In each case, direct bivalirudin delivery through a lysis catheter was associated with rapid resolution of thrombosis. Although study of more patients is needed to truly assess safety and efficacy, this series demonstrates that bivalirudin may be an effective drug for thrombolysis and should be considered in patients who have experienced bleeding or other complications from catheter-directed alteplase infusion.

Keywords: ECMO; VAD; bivalirudin; catheter-directed lysis; intracardiac thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The University of Colorado has received, on B.B.W.’s behalf, consulting fees from Sanofi and Takeda and research fees from NovoNordisk. The other authors have no conflicts of interest to report.

References

    1. Young G, Tarantino MD, Wohrley J, et al.: Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007: 1654, 1659.
    1. Rayapudi S, Torres A, Deshpande GG, et al.: Bivalirudin for anticoagulation in children. Pediatr Blood Cancer 51: 798–801, 2008.
    1. O’Brien SH, Yee DL, Lira J, Goldenberg NA, Young G: UNBLOCK: An open‐label, dose‐finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis. J Thromb Haemost 13: 1615–1622, 1622.
    1. Shammas NW: Bivalirudin: Pharmacology and clinical applications. Cardiovasc Drug Rev 23: 345–360, 2005.
    1. Nagle EL, Dager WE, Duby JJ, et al.: Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediat Crit Care Med 14: e182–e188, 2013.

LinkOut - more resources